Public Event Detail
A Look At Ligand Pharmaceuticals (LGND) Valuation After Earnings Miss XOMA Deal And Viking TR-Beta Termination
Public historical observation from the Merrowstone archive. This page shows event-level context only. Accepted assertions, evidence lineage, and relationship intelligence remain part of the premium research layer.
Event summary
Ligand Pharmaceuticals (LGND) recently reported an earnings miss, higher royalty revenues, a planned acquisition of XOMA, and a disputed termination of the Viking TR-Beta licensing program. Despite these developments, the stock has shown positive momentum over the past few months and is currently considered undervalued by analysts, trading at $220.48 against a narrative fair value of $246.70. The company's valuation is heavily influenced by its expanding high-margin royalty portfolio, although its P/E ratio of 28.8x is higher than the industry average, suggesting less room for error if expectations are not met.